A method for producing black ginseng concentrate is characterized by including steps of adding red ginseng to a continuous steaming-dryer followed by steaming, cooling, and drying to prepare black ginseng, carrying out extraction by adding alcohol to crushed black ginseng obtained by crushing the black ginseng prepared above followed by filtration to prepare black ginseng extract, and concentrating the black ginseng extract prepared above by using a plate type evaporative concentrator followed by heat treatment, and the present invention also relates to black ginseng concentrate prepared by the aforementioned method.

The present disclosure relates to a composition for preventing, alleviating or treating a neurodegenerative disease, which contains Pediococcus inopinatus as an active ingredient. The Pediococcus inopinatus strain according to the present disclosure can suppress neuroinflammation and can also alleviate the symptoms of ataxia in an animal model of Parkinson's disease and, thus, can be utilized for the prevention, alleviation and treatment of various neurodegenerative diseases including Parkinson's disease.

The present disclosure relates to a composition for preventing, alleviating or treating a neurodegenerative disease, which contains Pediococcus inopinatus as an active ingredient. The Pediococcus inopinatus strain according to the present disclosure can suppress neuroinflammation and can also alleviate the symptoms of ataxia in an animal model of Parkinson's disease and, thus, can be utilized for the prevention, alleviation and treatment of various neurodegenerative diseases including Parkinson's disease.

Choline alfoscerate is useful for treating cognitive dysfunction associated with cerebrovascular diseases and degenerative brain diseases. It is a drug with proven safety, which has no effect on the kidney and liver and with no severe side effect reported. When administered to a patient with neuropathic pain, it can significantly reduce the pain intensity and the occurrence of neuropathic pain. Accordingly, it may be used as an active ingredient in a pharmaceutical composition for treating or preventing neuropathic pain and a health functional food composition for improving neuropathic pain and may also be used for a method for treating neuropathic pain by administering choline alfoscerate. In addition, choline alfoscerate may also be used to prepare a medication for treating neuropathic pain.

Choline alfoscerate is useful for treating cognitive dysfunction associated with cerebrovascular diseases and degenerative brain diseases. It is a drug with proven safety, which has no effect on the kidney and liver and with no severe side effect reported. When administered to a patient with neuropathic pain, it can significantly reduce the pain intensity and the occurrence of neuropathic pain. Accordingly, it may be used as an active ingredient in a pharmaceutical composition for treating or preventing neuropathic pain and a health functional food composition for improving neuropathic pain and may also be used for a method for treating neuropathic pain by administering choline alfoscerate. In addition, choline alfoscerate may also be used to prepare a medication for treating neuropathic pain.

The present disclosure relates to a composition for preventing, alleviating or treating depression or anxiety disorder, which contains Lactobacillus sakei as an active ingredient. The Lactobacillus sakei strain according to the present disclosure can be used to prevent, alleviate or treat a mental disorder such as depression or anxiety disorder.

The present disclosure relates to a composition for preventing, alleviating or treating depression or anxiety disorder, which contains Lactobacillus sakei as an active ingredient. The Lactobacillus sakei strain according to the present disclosure can be used to prevent, alleviate or treat a mental disorder such as depression or anxiety disorder.

The present invention relates to a pharmaceutical composition comprising calcium pantothenate, or calcium pantothenate and dimenhydrinate as active ingredients for prevention and treatment of myopathy. According to the present disclosure, calcium pantothenate upregulates the expression of MHC, myogenin 4-EBP, and p70S6K to promote myoblast differentiation and myogenesis, thereby prolonging the duration of life in amyotrophic lateral sclerosis patients and promoting the growth of MSC in Duchenne muscular dystrophy mice. Such effects are synergistically increased upon combined treatment with dimenhydrinate. Thus, they can be advantageously used for preventing or treating myopathy.

The present invention provides a beverage containing pyrroloquinoline quinone and/or a salt thereof, an amino acid and/or a salt thereof, and ascorbic acid and/or a salt thereof, wherein the content of ascorbic acid and/or a salt thereof is two or more mass times the content of pyrroloquinoline quinone and/or a salt thereof.

The present invention provides a beverage containing pyrroloquinoline quinone and/or a salt thereof, an amino acid and/or a salt thereof, and ascorbic acid and/or a salt thereof, wherein the content of ascorbic acid and/or a salt thereof is two or more mass times the content of pyrroloquinoline quinone and/or a salt thereof.